Ultime notizie per Solid Power (NASDAQ:SLDP) Azioni

Solid Power

Solid Power Inc is engaged in solid-state battery technology and manufacturing processes. Its core technology is a sulfide-based solid electrolyte material, which replaces the liquid or gel electrolyte used in traditional lithium-ion battery cells. Its commercialization plan is to manufacture and sell electrolytes to Tier 1 battery manufacturers and automotive original equipment manufacturers (OEMs) that choose to produce its battery cells.

Stuttgart,,Germany,-,05-22-2021:,Mobile,Phone,With,Logo,Of,Us

Long Ideas

News

Markets

Media

Trading Ideas

ENVX

SBUX

SLDP

Il noto analista di Wall Street passa in rassegna alcuni dei nomi più hot. Tra &#34;buy&#34;, &#34;sell&#34; e avvertimenti, ecco i suoi ultimi verdetti.

&#34;Comprare ora&#34;: il consiglio di Jim Cramer su 5 titoli da monitorare

Solid Power Inc

Citigroup analyst Yigal Nochomovitz maintains Apellis Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APLS#NASDAQ">APLS</a>) with a Buy and raises the price target from $41 to $46.

Price Target

Analyst Ratings

APLS

Citigroup Maintains Buy on Apellis Pharmaceuticals, Raises Price Target to $46

WIIM

APLS stock has given up its prior gain. Apellis Pharmaceuticals shares were trading higher after the company announced it has won FDA approval for EMPAVELI.

Citigroup analyst Peter Christiansen maintains Coinbase Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>) with a Buy and raises the price target from $270 to $505.

COIN

Citigroup Maintains Buy on Coinbase Global, Raises Price Target to $505

Macro Notification

Politics

Economics

General

Live On CNBC, U.S. Treasury's Bessent On China Trade Says Tik Tok Not Discussed; Taiwanese Movements Not Part Of Talks; In 90 Days Don't Know Where We're Going To Be;  Good News Is We're Talking; Now We Have Communications At All Levels

Tapestry, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TPR#NYSE">TPR</a>) stock declined Tuesday as analysts reassessed its valuation despite ongoing <a href="https://www.benzinga.com/quote/TPR/analyst-ratings" target="_blank" rel="noreferrer noopener">strength in the Coach brand</a>.
Bank of America Securities analyst Lorraine Hutchinson downgraded Tapestry from Buy to Hold on Tuesday, raising the price forecast from $95 to $115.
Hutchinson observes that while the Coach brand is set to deliver several more quarters of strong growth, the stock's 66% year-to-date rally, far outpacing the S&amp;P's 9%, has brought its valuation close to fair value.
Also Read: <a href="https://www.benzinga.com/markets/large-cap/25/07/46413056/tapestry-ups-investment-in-recycled-leather-pioneer-gen-phoenix" target="_blank" rel="noreferrer noopener">Coach Parent Tapestry Ups Investment In Recycled Leather Pioneer Gen Phoenix</a>
Over the past decade, Tapestry has traded at an average P/E of 13x, ranging between 6x and 20x, and is now sitting at the upper end of that range. As a result, she has moved to a Neutral stance, despite raising the price objective.
Hutchinson also anticipates a solid fourth quarter, forecasting EPS of 98 cents, matching management's guidance, and expects 5.4% sales growth and a 16.4% operating margin, while noting that a delayed Summer Sale may have boosted late-quarter sales, likely prompting an upbeat tone on the earnings call.
Hutchinson notes that fiscal year 2026 guidance will be closely watched, with expectations for mid-single-digit sales growth and stable margins, balancing tariff-related pressures with some SG&amp;A efficiency.
The analyst highlights that Coach continues to perform well, driven by successful marketing and premium product appeal, but doesn't foresee management forecasting double-digit growth for the brand this year.
While there's room for upside in fiscal year 2026 estimates, the analyst sees limited long-term margin expansion beyond Coach's already elevated 33.6% operating margin.
On tariffs, Hutchinson sees management can maintain profitability over time, though mitigation efforts will take a few quarters to ramp; the analyst projects a 60bp fiscal year 2026 gross margin decline from tariffs, with full recovery by fiscal year 2027, assuming initiatives scale and higher tariff rates accelerate those adjustments.
Price Action: TPR shares are trading lower by 2.35% to $107.83 at last check Tuesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/personal-finance/25/04/44656550/grant-cardone-roasts-luxury-items-and-recommends-real-estate-instead-birkin-bags-are-not-investments" target="_blank" rel="noreferrer noopener">Grant Cardone Roasts Luxury Items and Recommends Real Estate Instead: ‘Birkin Bags Are Not Investments'</a></li>
</ul>
Image via Shutterstock

Analyst Color

Equities

Downgrades

Movers

Why Tapestry Stock Is Cooling Off Despite Coach's Hot Streak

Bausch Health Companies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BHC#NYSE">BHC</a>) on Tuesday agreed to indirectly acquire DURECT Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DRRX#NASDAQ">DRRX</a>), including a novel <a href="https://www.benzinga.com/general/health-care" target="_blank" rel="noreferrer noopener">therapeutic molecule, larsucosterol</a>.
Larsucosterol, an endogenous sulfated oxysterol and an epigenetic modulator, has demonstrated promising results for alcoholic hepatitis (AH) in Phase 2 trials.
Alcoholic hepatitis is&nbsp;a severe liver inflammation caused by excessive alcohol consumption.&nbsp;It is characterized by the rapid onset of jaundice and liver enlargement.
Bausch Health&#8217;s hepatology development and commercial capabilities are well-suited to support the clinical development and potential commercialization of larsucosterol.
The companies add that there is currently no Food and Drug Administration- or European Medicines Agency-approved treatment for AH.
Also Read: <a href="https://www.benzinga.com/general/biotech/25/05/45471704/icahn-ramps-up-bets-on-genes-and-jets-illumina-stake-jumps-450-jetblue-holding-grow-90" target="_blank" rel="noreferrer noopener">Icahn Ramps Up Bets On Genes And Jets: Illumina Stake Jumps 450%, JetBlue Holding Grow 90%</a>
Bausch Health will pay $1.75 per share in an all-cash transaction for an upfront consideration of approximately $63 million, with the potential for two additional net sales milestone payments of up to $350 million.
A registrational Phase 3 program to evaluate the safety and efficacy of larsucosterol for the treatment of patients with severe AH is being planned.
The trial will be a randomized, double-blind, placebo-controlled, multi-center study. The primary endpoint will be 90-day survival.
The trial design will incorporate feedback received from the FDA during a Type B meeting under Breakthrough Therapy Designation and learnings from the prior Phase 2b AHFIRM trial in AH.
The acquisition of the clinical development program for larsucosterol in AH complements the ongoing Bausch Health RED-C clinical program, which is designed to assess the efficacy of a next-generation therapeutic, rifaximin SSD, to delay the onset of first overt hepatic encephalopathy (OHE) hospitalization and all-cause mortality.
Patient enrollment in two global Phase 3 studies is now complete with efficacy and safety results expected to be announced in early 2026.
The transaction is expected to close in the third quarter of 2025.
Last year, Bausch Health <a href="https://www.benzinga.com/news/large-cap/24/10/41313679/bausch-lomb-sale-process-gains-momentum-as-tpg-and-blackstone-join-forces" target="_blank" rel="noreferrer noopener">was in talks with several</a> private equity firms about selling Bausch + Lomb Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BLCO#NYSE">BLCO</a>).
The Bausch + Lomb spin-off was part of Bausch Health's plan to alleviate its $21 billion debt, a third&nbsp;<a target="_blank" href="https://www.benzinga.com/news/large-cap/24/09/40884021/contact-lens-supplier-bausch-lomb-eyes-sale-amid-separation-challenges-as-parent-bausch-health-fac" rel="noreferrer noopener">of which is due by 2027</a>.
BHC, DRRX Price Actions: Bausch Health stock is down 0.36% at $6.87, and DURECT stock is up 238.34% at $1.87 at publication on Tuesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/earnings/25/07/46688163/unitedhealth-misses-q2-mark-but-vows-a-healthier-2026" target="_blank" rel="noreferrer noopener">UnitedHealth Misses Q2 Mark But Vows A Healthier 2026</a></li>
</ul>
Photo: Shutterstock

Biotech

Large Cap

Health Care

BLCO

DRRX

Bausch Health Adds Late-Stage Ready Alcohol Liver Disease Drug Candidate In $63 Million DURECT Buyout

Rosenblatt analyst Kevin Cassidy maintains Rambus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RMBS#NASDAQ">RMBS</a>) with a Buy and raises the price target from $80 to $90.

RMBS

Rosenblatt Maintains Buy on Rambus, Raises Price Target to $90

Live On CNBC, U.S. Treasury's Bessent On Aug. 1 Trade Deadline Says Not End Of World If Tariffs Snap Back For Days Or Weeks As Long As Countries Trying To Negotiate; Happy To Do Deal Or Can Just Have Tariff Income

Live On CNBC, U.S. Treasury's Bessent On Vietnam Trade Says Assume We Have Confirmed Deal

Macro Economic Events

Live On CNBC, U.S. Treasury's Bessent On EU Trade And $600B Investments Says Will Be Closely Monitored; Would Be Surprised If EU Doesn't Hold Up Bargain, Tariff Rates Can Change; Portion Could Be For Defense, Agriculture

Maxim Group analyst Michael Diana maintains Two Harbors Inv (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TWO#NYSE">TWO</a>) with a Buy and lowers the price target from $15 to $12.

Maxim Group Maintains Buy on Two Harbors Inv, Lowers Price Target to $12

Live On CNBC, U.S. Treasury's Bessent On China Talks Says Urged China To Move Toward Consumer Economy, Away From Manufacturing; On Possible Trump-Xi Meeting Says That Will Be Between Leaders' Staffs; On China, Iran Oil Says Beijing Said They Are A Sovereign Nation With Security, Energy Needs; On Whether U.S. Has Leverage On China Iran Oil Says  Not At This Point; On China Says May Take External Forces To Push Economy To Consumer Focus

Lake Street analyst Ben Haynor maintains Ekso Bionics Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EKSO#NASDAQ">EKSO</a>) with a Buy and lowers the price target from $15 to $9.5.

EKSO

Lake Street Maintains Buy on Ekso Bionics Holdings, Lowers Price Target to $9.5

<a href="https://www.axios.com/pro/energy-policy/2025/07/29/nuclear-overhaul-trump">https://www.axios.com/pro/energy-policy/2025/07/29/nuclear-overhaul-trump</a>

OKLO

'NRC overhaul and departures prompt fears of slowing process'- Axios

Live On CNBC, U.S. Treasury's Bessent On China Trade Says Discusses Big Economic Frameworks; On Aug 12 Deadline Says Pends Trump's Approval; Trump Will Make Final Decision; On China Trade Says Meetings Robust; Continue To Perfect Rare Earth Systems

Barclays analyst David Strauss maintains Textron (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TXT#NYSE">TXT</a>) with a Overweight and raises the price target from $95 to $105.

Barclays Maintains Overweight on Textron, Raises Price Target to $105

American Tower Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMT#NYSE">AMT</a>) shares are<a href="https://www.benzinga.com/movers" target="_blank" rel="noreferrer noopener"> trading lower on Tuesday</a> following the release of its second-quarter results.
The company reported second-quarter results, where total revenue <a href="https://www.benzinga.com/pressreleases/25/07/b46682856/american-tower-corporation-reports-second-quarter-2025-financial-results" target="_blank" rel="noreferrer noopener">increased 3.2% to $2.63 billion</a>. Adjusted EBITDA increased 1.8% to $1.75 billion.
According to Goldman Sachs analyst James Schneider, the stock is likely to remain range-bound, as the results and 2025 guidance <a href="https://www.benzinga.com/quote/AMT/analyst-ratings" target="_blank" rel="noreferrer noopener">generally align with Street expectations</a>.
Also Read: <a href="https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/07/46697856/cadence-design-systems-delivers-beat-and-raise-quarter-despite-us-export-bans" target="_blank" rel="noreferrer noopener">Cadence Design Systems Delivers Beat-And-Raise Quarter Despite US Export Bans</a>
Schneider adds that investors seem optimistic about American Tower due to stronger domestic organic growth heading into year-end, the possibility of a cost-cutting update in the second half of 2025, and sector-leading Adjusted Funds From Operations (AFFO) per share growth.
The analyst also points out that American Tower has indirectly benefited from macro trends such as a weaker U.S. dollar and currency movements, which are reflected in the revised guidance.
With Crown Castle (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CCI#NYSE">CCI</a>) delivering better-than-expected results and raising its 2025 domestic activity outlook, investors may expect similarly upbeat commentary from American Tower's earnings call.
Schneider mentions that American Tower&#8217;s 2025 core guidance largely matches Street expectations, with a slight improvement in international outlook but a small decline in U.S. organic growth projections.
The analyst also outlines potential downside risks, including additional strain on core tower leasing, international macroeconomic challenges, sustained high interest rates, and unfavorable foreign exchange movements.
Schneider reiterated the Buy rating on American Tower with a price forecast of $250.
Price Action: AMT shares are trading lower by 3.51% to $216.28 at last check Tuesday. &nbsp;
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/equities/25/06/46111337/micron-ceo-cautions-ai-boom-may-not-be-fully-sustainable-flags-tariff-driven-demand-pull-in" target="_blank" rel="noreferrer noopener">Goldman Sachs: 4 Must-Buy Chip Stocks, And A Few You Should Forget</a></li>
</ul>
Photo via Shutterstock

Reiteration

Tech

American Tower Sees Slightly Weaker US Growth As International Performance Strengthens

<a href="https://x.com/elonmusk/status/1950255503545626757?s=46&amp;t=dtUiyC3dUs5yGRgT9qYHWg">https://x.com/elonmusk/status/1950255503545626757?s=46&amp;t=dtUiyC3dUs5yGRgT9qYHWg</a>

SSNLF

TSLA

Elon Musk Posts On X "They do. I had a video call with the chairman and senior leadership of Samsung to go over what a real partnership would be like. Use the strengths of both companies to achieve a great outcome."

Dividends

CTAS

Cintas Corporation Increases Its Quarterly Cash Dividend From $0.39 To $0.45

Virtu Finl (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VIRT#NASDAQ">VIRT</a>) will release its quarterly earnings report on Wednesday, 2025-07-30. Here's a brief overview for investors ahead of the announcement.
Analysts anticipate Virtu Finl to report an earnings per share (EPS) of $1.31.
The announcement from Virtu Finl is eagerly anticipated, with investors seeking news of surpassing estimates and favorable guidance for the next quarter.
It's worth noting for new investors that guidance can be a key determinant of stock price movements.
<h3>Historical Earnings Performance</h3>
The company's EPS beat by $0.11 in the last quarter, leading to a 1.46% drop in the share price on the following day.
Here's a look at Virtu Finl's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q1 2025</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>1.19</td>
<td>0.89</td>
<td>0.79</td>
<td>0.60</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>1.30</td>
<td>1.14</td>
<td>0.82</td>
<td>0.83</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-1.0%</td>
<td>0.0%</td>
<td>0.0%</td>
<td>6.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1753812209_0.png" alt="eps graph" />
<h3>Tracking Virtu Finl's Stock Performance</h3>
Shares of Virtu Finl were trading at $43.4 as of July 28. Over the last 52-week period, shares are up 60.58%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. 
<h3>Insights Shared by Analysts on Virtu Finl</h3>
For investors, staying informed about market sentiments and expectations in the industry is paramount. This analysis provides an exploration of the latest insights on Virtu Finl.
A total of 3 analyst ratings have been received for Virtu Finl, with the consensus rating being Neutral. The average one-year price target stands at $42.0, suggesting a potential 3.23% downside.
<h3>Analyzing Ratings Among Peers</h3>
In this comparison, we explore the analyst ratings and average 1-year price targets of PJT Partners, Marex Group and Lazard, three prominent industry players, offering insights into their relative performance expectations and market positioning.
<ul>
<li>Analysts currently favor an Neutral trajectory for PJT Partners, with an average 1-year price target of $180.0, suggesting a potential 314.75% upside.</li>
<li>Analysts currently favor an Outperform trajectory for Marex Group, with an average 1-year price target of $51.33, suggesting a potential 18.27% upside.</li>
<li>Analysts currently favor an Neutral trajectory for Lazard, with an average 1-year price target of $51.25, suggesting a potential 18.09% upside.</li>
</ul>
<h3>Peer Metrics Summary</h3>
The peer analysis summary outlines pivotal metrics for PJT Partners, Marex Group and Lazard, demonstrating their respective standings within the industry and offering valuable insights into their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Virtu Finl</td>
<td>Neutral</td>
<td>30.34%</td>
<td>$496.64M</td>
<td>7.28%</td>
</tr>
<tr>
<td>PJT Partners</td>
<td>Neutral</td>
<td>-1.48%</td>
<td>$103.39M</td>
<td>32.17%</td>
</tr>
<tr>
<td>Marex Group</td>
<td>Outperform</td>
<td>28.23%</td>
<td>$321M</td>
<td>7.17%</td>
</tr>
<tr>
<td>Lazard</td>
<td>Neutral</td>
<td>16.23%</td>
<td>$288.75M</td>
<td>8.10%</td>
</tr>
</tbody>
</table>

Key Takeaway:
Virtu Finl ranks at the top for Revenue Growth and Gross Profit among its peers. However, it ranks at the bottom for Return on Equity. Overall, Virtu Finl is positioned well compared to its peers in terms of financial performance metrics.
<h3>Get to Know Virtu Finl Better</h3>
Virtu Financial Inc is a financial firm that leverages technology to deliver liquidity to the world-wide markets and transparent trading solutions to its clients. The company's operating segment includes Market Making; and Execution Services. The non-operating segment of the company includes the Corporate segment. The company generates maximum revenue from the market-making segment. The Market Making segment principally consists of market-making in the cash, futures, and options markets across equities, options, fixed income, currencies, and commodities. Geographically, it derives a majority of its revenue from the United States and also has a presence in Ireland and Other Countries.
<h3>Virtu Finl's Economic Impact: An Analysis</h3>
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
Revenue Growth: Virtu Finl displayed positive results in 3 months. As of 31 March, 2025, the company achieved a solid revenue growth rate of approximately 30.34%. This indicates a notable increase in the company's top-line earnings. When compared to others in the Financials sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: Virtu Finl's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of 11.14%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Virtu Finl's ROE excels beyond industry benchmarks, reaching 7.28%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Virtu Finl's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of 0.57%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: With a high debt-to-equity ratio of 5.99, Virtu Finl faces challenges in effectively managing its debt levels, indicating potential financial strain.
<a href="https://www.benzinga.com/quote/VIRT/earnings">To track all earnings releases for Virtu Finl visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings

VIRT

Virtu Finl's Earnings Outlook

Financing

Press Releases

Solid Power Selected by U.S. Department of Energy for Up to $50 Million Award Negotiation for Continuous Production of Sulfide-based Solid Electrolyte Materials for Advanced All-Solid-State Batteries

Solid Power, Inc. Announces Timing of Third Quarter 2024 Earnings Release and Conference Call

Solid Power Reports Third Quarter 2024 Results

How Battery Cell Technology is Playing an Extremely Vital Role in Space Exploration

Solid Power Announces Upcoming Investor Conference Participation

Solid Power, Inc. Announces Timing of Full Year 2024 Earnings Release and Conference Call

Solid Power Reports Full Year 2024 Results

Solid Power, Inc. Announces Timing of First Quarter 2025 Earnings Release and Conference Call

Solid Power Reports First Quarter 2025 Results

Solid Power, Inc. Announces Timing of Second Quarter 2025 Earnings Release and Conference Call

KULR

LUNR

RKLB

SLDPW

Adient

Autoliv

American Axle & Manufacturing Holdings, Inc. Common Stock

American Axle & Mfg Hldgs

BorgWarner

Cooper-Standard Holdings Inc. Common Stock

Cooper-Standard Holdings

Dana

Dorman Products

ECARX Holdings Inc. - Class A Ordinary shares

ECARX Holdings

Fox Factory Holding

Gentex

Garrett Motion

Holley

Hesai Group - American Depositary Share, each ADS represents one Class B ordinary share

Comments

Solid Power

Notizie

Ultime notizie per Solid Power (NASDAQ:SLDP) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO